Milestones :: Perspectives :: Research
India: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment
Ministry of Health and Family Welfare
Genomic Surveillance for SARS-CoV-2 In India: Indian SARS-CoV-2 Genomics Consortium (INSACOG) (Updated guidelines and SOPs)
… Indian SARS-CoV-2 Genomics Consortium (INSACOG) was established to expand Whole
Genome Sequencing of SARS-CoV-2 across the nation, aiding our understanding of how the virus
spreads and evolves. The Consortium had initially started with a network of ten regional genome
sequencing laboratories spread across the country and has now been expanded to currently include
28 INSACOG Genome Sequencing Laboratories (IGSLs) that are mapped to the States and UTs
for facilitating smooth flow of samples. The viral genome sequencing data generated by these
IGSLs is analysed by the respective centres and sent to the National Centre for Disease Control
(NCDC), Delhi for collation and integration…
Government of India – Press Information Bureau
Latest Press Releases
The approval for world’s first DNA based ‘ZyCov-D’ vaccine of Zydus Universe is a testimony to the innovative zeal of India’s scientists: PM
Posted on: 20 Aug 2021
The Prime Minister, Shri Narendra Modi has said that the approval for world’s first DNA based ‘ZyCov-D’ vaccine of is a testimony to the innovative zeal of India’s scientists.
In response to a tweet by CDSCO India Info, the Prime Minister said; “India is fighting COVID-19 with full vigour. The approval for world’s first DNA based ‘ZyCov-D’ vaccine of @ZydusUniverse is a testimony to the innovative zeal of India’s scientists. A momentous feat indeed.”
After evaluation of interim Phase III clinical trial results in consultation with Subject Expert Committee, CDSCO has approved DNA COVID-19 vaccine (ZyCoV-D) of M/s Cadila Healthcare for restricted use in emergency situation in India for 12 years and above.
Zydus receives EUA from DCGI for ZyCoV-D, the only needle-free COVID vaccine in the world
:: World’s first Plasmid DNA Vaccine for COVID-19, ZyCoV-D will be administered in three
:: Apart from adults, for the first time adolescents in the age group of 12-18 years will take the
vaccine shot in India.
:: Safety, efficacy and immunogenicity of the vaccine is well established.
:: Company begins stockpiling of the vaccine.
Ahmedabad, August 20, 2021,
Zydus Cadila today announced that the company has received the Emergency Use Authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D the world’s first Plasmid DNA Vaccine for COVID-19. ZyCoV-D is a three dose vaccine which will be administered first on day zero, day 28th and then on the 56th day. With this approval, India now has its first COVID-19 vaccine for the adolescents in the 12-18 age group, besides the adult population. ZyCoV-D, is a needle-free vaccine administered using The PharmaJet® a needle free applicator, which ensures painless intradermal vaccine delivery.
This is for the first time that a technologically advanced vaccine has been successfully developed on the Plasmid DNA platform for human use. The platform because of its rapid plug and play technology can be easily adapted to deal with mutations in the virus, such as those already occurring. The company plans to manufacture 10-12 crore doses of ZyCoV-D annually.
Speaking on this development, Mr. Pankaj R. Patel, Chairman, Cadila Healthcare Ltd., said “This is a historic milestone with ZyCoV-D, a product of Indian innovation becoming the world’s first DNA vaccine being offered for human use and supporting the world’s largest immunization drive. We are particularly happy that our vaccine will contribute to this fight against COVID-19 and enable the country to vaccinate a larger population especially in the age group of 12-18 years. I would like to thank all the researchers, clinical trial investigators, volunteers and the regulators who have supported this endeavour.”
The company also plans to seek approval for the two dose regimen of the vaccine. The main advantage of DNA vaccines is their ability to stimulate both the humoral and cellular arms of the adaptive immune system. They are a valuable form of antigen-specific immunotherapy, as they are safe, stable and can be easily produced. Zydus acknowledges the support of National Biopharma Mission, BIRAC, Department of Biotechnology, Govt of India, National Institute of Virology, Indian Council of Medical Research and PharmaJet® in the development of ZyCoV-D vaccine…
Indian Council for Medical Research (ICMR)
India achieves milestone of 50 crores COVID-19 Sample Testing